key: cord-0699526-1tzagl7j
authors: Ye, Qing; Lai, En Yin; Luft, Friedrich C.; Persson, Pontus B.; Mao, Jianhua
title: SARS‐CoV‐2 effects on the renin‐angiotensin‐aldosterone system, therapeutic implications
date: 2021-01-07
journal: Acta Physiol (Oxf)
DOI: 10.1111/apha.13608
sha: 98f35a3e545af7a71e8cae33d33621d33bcc8ffe
doc_id: 699526
cord_uid: 1tzagl7j

Angiotensin converting enzyme-2 (ACE-2) is the cell-surface receptor enabling viral uptake of corona virus 2019 (SARS-CoV-2), thus ACE-2 is a first step towards COVID-19 disease. ACE-2 is a metalloenzyme located primarily on the apical surface, and serves as the entry point also for other coronaviruses, including HCoV-NL63 and SARS-CoV. Throughout evolution, ACE-2 precedes renin, suggesting that ACE-2's role changed over time.1.

the activity of the latter and shift ACE/ACE-2 balance to a state of enhanced ANGII activity, which leads to vasoconstriction and inflammatory 5 and oxidative organ damage, and further promotes damage. 6 The use of RAS inhibitors can increase expression of ACE-2 on the tissue and apical surface to a certain extent. Therefore, the use of ACEIs or ARBs to treat diseases is considered likely to increase the risk of SARS-CoV-2 exposure. However, so far, there is no experimental evidence indicating that ACEIs or ARBs augment the susceptibility to SARS-CoV-2 or aggravate the outcomes and severity of COVID-19. Accordingly, large observational studies have not shown any association with increased COVID-19 risk and patients who are receiving ACE inhibitors or ARBs. 7 After SARS-CoV infection in mice, ACE-2 protein levels are greatly reduced, depending on virus replication, which is consistent with the situation in host cells. 8 Additionally, SARS-CoV-2 can weaken the activity of ACE-2 by binding to ACE-2. In consequence, elevated ANGII further aggravates kidney injury by activating AT 1 R, causing inflammation and fibrosis. Inhibiting RAS by ACEIs/ARBs or recombinant ACE-2 increases expression of ACE-2, thereby reducing ANGII levels and enhancing Ang-(1-7) generation. Increased ACE-2 expression promotes the activation of Mas receptor (MasR), which in turn attenuates inflammation and fibrosis, and therefore attenuates kidney injury. 9 Moreover, the increase in the level of soluble ACE-2 may also neutralize SARS-CoV-2, limit virus entry and reduce tissue damage. Therefore, providing RAS inhibitors seems advantageous for COVID-19 patients ( Figure 1A) . Indeed, observational cohort studies, and randomized trials for other endpoints provide no evidence for adverse effects RAS inhibition in COVID-19. 7 Thus, RAS inhibitors should not be withheld from patients because of any SARS-CoV-2 concerns. 10, 11 The contrary may hold true.

Monteil et al 12 reported that infection with SARS-CoV-2 can be inhibited with a human recombinant soluble ACE-2 (hrsACE-2). The hrsACE-2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1000-5000. The investigators also showed that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE-2. Other sophisticated approaches are suggested by Chan et al 13 By using deep mutagenesis, that group identified mutations in ACE-2 that increased spike protein binding across the interaction surface, in the asparagine 90-glycosylation motif, and at buried sites. The mutational landscape provided the group with a blueprint for understanding the specificity of the interaction between ACE-2 and spike protein, as well as for engineering high-affinity decoy receptors. Combining mutations brought up ACE-2 variants affinities that rival those of monoclonal antibodies. A stable dimeric variant reveals potent SARS-CoV-2 and SARS-CoV neutralization in vitro. The engineered soluble ACE-2 receptor was catalytically active, and its close similarity with the native receptor could limit the potential for viral escape ( Figure 1B) . These novel approaches could help us therapeutically in the future.

Emergence and evolution of the renin-angiotensin-aldosterone system

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

Reactive oxygen species in renal vascular function

Renin-angiotensin-aldosterone system inhibitors in patients with covid-19

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin type 2 receptor null mice express reduced levels of renal angiotensin II type 2 receptor/angiotensin (1-7)/Mas receptor and exhibit greater high-fat diet-induced kidney injury

Joint HFSA/ACC/AHA statement addresses concerns Re: using RAAS antagonists in COVID-19

Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2